Report Detail

Request for Sample of this report

Pharma & Healthcare Global Human High-density Lipoprotein Particles Market 2026 by Company, Regions, Type and Application, Forecast to 2032

  • RnM4685767
    • |
  • 12 March, 2026
    • |
  • Global
    • |
  • 130 Pages
    • |
  • GIR
    • |
  • Pharma & Healthcare

According to our (Global Info Research) latest study, the global Human High-density Lipoprotein Particles market size was valued at US$ 109 million in 2025 and is forecast to a readjusted size of US$ 236 million by 2032 with a CAGR of 11.7% during review period.
Human high-density lipoprotein (HDL) particles are a type of natural lipoprotein complex derived from human plasma. They typically have apolipoprotein A-I (ApoA-I) as their core framework, with an outer layer composed of phospholipids and free cholesterol, and an interior rich in cholesterol esters and accompanied by small amounts of triglycerides. These particles primarily function as reverse cholesterol transporters in the body, transporting excess cholesterol from peripheral tissues and blood vessel walls back to the liver for metabolism and clearance. They also possess anti-inflammatory, antioxidant, and endothelial protective biological activities. Due to their preservation of natural conformation and functional properties, human HDL particles are widely used in basic and translational medical research related to cardiovascular diseases, lipid metabolism, inflammatory responses, and drug mechanisms. In 2025, sales volume was 356,000 units, with an average price of $300, total production capacity of 400,000 units, and a gross profit margin of 82%.
From the demand side, the market for human high-density lipoprotein (HDL) particles is primarily driven by three types of demand: basic research, translational medicine, and in vitro diagnostic (IVD) raw materials. In research areas such as atherosclerosis, inflammatory responses, reverse cholesterol transport, and immunometabolism, HDL is considered a key functional biological particle, maintaining stable demand in universities, research institutions, and early-stage drug development at pharmaceutical companies. Simultaneously, some IVD manufacturers are increasingly reliant on controllable and batch-consistent human HDL standards when developing lipid function-related detection projects, driving the typical characteristics of this niche market: "small volume, high unit price, and strong professional barriers."
From the supply and trend perspective, the current market is still dominated by research-grade products, with supply concentrated among a few manufacturers possessing qualifications for human plasma processing, biological separation and purification capabilities, and compliant systems. The industry has high barriers to entry. In the future, on the one hand, as technologies for synthetic HDL, recombinant apolipoprotein A-I, and engineered lipoprotein particles mature, some application scenarios may see a replacement of traditional human HDL; on the other hand, in the short term, the irreplaceable nature of highly reliable "authentic human particles" in mechanistic research and methodological validation will continue to support its market position, allowing this field to maintain high added value and strong customer loyalty despite the relatively small volume.
This report is a detailed and comprehensive analysis for global Human High-density Lipoprotein Particles market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Human High-density Lipoprotein Particles market size and forecasts, in consumption value ($ Million), 2021-2032
Global Human High-density Lipoprotein Particles market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Human High-density Lipoprotein Particles market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Human High-density Lipoprotein Particles market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Human High-density Lipoprotein Particles
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Human High-density Lipoprotein Particles market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Amgen, Betta Pharmaceuticals, Thermo Fisher Scientific Inc., Eli Lilly and Company, Bio-Techne, Merck, Yeasen, Sino Biological, Miltenyi Biotec, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Human High-density Lipoprotein Particles market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Purity＞95%
Purity≤95%
Market segment by Functional State
HDL₂
HDL₃
Market segment by Apolipoprotein Composition
ApoA-I-containing HDL
ApoA-I/ApoA-II HDL
Market segment by Application
Biological Laboratories
University
Others
Market segment by players, this report covers
Novartis
Amgen
Betta Pharmaceuticals
Thermo Fisher Scientific Inc.
Eli Lilly and Company
Bio-Techne
Merck
Yeasen
Sino Biological
Miltenyi Biotec
Proteintech
BioLegend
MP Biomedicals
Molecular Depot
Biosynth
Assaypro
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Human High-density Lipoprotein Particles product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Human High-density Lipoprotein Particles, with revenue, gross margin, and global market share of Human High-density Lipoprotein Particles from 2021 to 2026.
Chapter 3, the Human High-density Lipoprotein Particles competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Human High-density Lipoprotein Particles market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Human High-density Lipoprotein Particles.
Chapter 13, to describe Human High-density Lipoprotein Particles research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Human High-density Lipoprotein Particles by Type
    • 1.3.1 Overview: Global Human High-density Lipoprotein Particles Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Human High-density Lipoprotein Particles Consumption Value Market Share by Type in 2025
    • 1.3.3 Purity＞95%
    • 1.3.4 Purity≤95%
  • 1.4 Classification of Human High-density Lipoprotein Particles by Functional State
    • 1.4.1 Overview: Global Human High-density Lipoprotein Particles Market Size by Functional State: 2021 Versus 2025 Versus 2032
    • 1.4.2 Global Human High-density Lipoprotein Particles Consumption Value Market Share by Functional State in 2025
    • 1.4.3 HDL₂
    • 1.4.4 HDL₃
  • 1.5 Classification of Human High-density Lipoprotein Particles by Apolipoprotein Composition
    • 1.5.1 Overview: Global Human High-density Lipoprotein Particles Market Size by Apolipoprotein Composition: 2021 Versus 2025 Versus 2032
    • 1.5.2 Global Human High-density Lipoprotein Particles Consumption Value Market Share by Apolipoprotein Composition in 2025
    • 1.5.3 ApoA-I-containing HDL
    • 1.5.4 ApoA-I/ApoA-II HDL
  • 1.6 Global Human High-density Lipoprotein Particles Market by Application
    • 1.6.1 Overview: Global Human High-density Lipoprotein Particles Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.6.2 Biological Laboratories
    • 1.6.3 University
    • 1.6.4 Others
  • 1.7 Global Human High-density Lipoprotein Particles Market Size & Forecast
  • 1.8 Global Human High-density Lipoprotein Particles Market Size and Forecast by Region
    • 1.8.1 Global Human High-density Lipoprotein Particles Market Size by Region: 2021 VS 2025 VS 2032
    • 1.8.2 Global Human High-density Lipoprotein Particles Market Size by Region, (2021-2032)
    • 1.8.3 North America Human High-density Lipoprotein Particles Market Size and Prospect (2021-2032)
    • 1.8.4 Europe Human High-density Lipoprotein Particles Market Size and Prospect (2021-2032)
    • 1.8.5 Asia-Pacific Human High-density Lipoprotein Particles Market Size and Prospect (2021-2032)
    • 1.8.6 South America Human High-density Lipoprotein Particles Market Size and Prospect (2021-2032)
    • 1.8.7 Middle East & Africa Human High-density Lipoprotein Particles Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Novartis
    • 2.1.1 Novartis Details
    • 2.1.2 Novartis Major Business
    • 2.1.3 Novartis Human High-density Lipoprotein Particles Product and Solutions
    • 2.1.4 Novartis Human High-density Lipoprotein Particles Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Novartis Recent Developments and Future Plans
  • 2.2 Amgen
    • 2.2.1 Amgen Details
    • 2.2.2 Amgen Major Business
    • 2.2.3 Amgen Human High-density Lipoprotein Particles Product and Solutions
    • 2.2.4 Amgen Human High-density Lipoprotein Particles Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Amgen Recent Developments and Future Plans
  • 2.3 Betta Pharmaceuticals
    • 2.3.1 Betta Pharmaceuticals Details
    • 2.3.2 Betta Pharmaceuticals Major Business
    • 2.3.3 Betta Pharmaceuticals Human High-density Lipoprotein Particles Product and Solutions
    • 2.3.4 Betta Pharmaceuticals Human High-density Lipoprotein Particles Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Betta Pharmaceuticals Recent Developments and Future Plans
  • 2.4 Thermo Fisher Scientific Inc.
    • 2.4.1 Thermo Fisher Scientific Inc. Details
    • 2.4.2 Thermo Fisher Scientific Inc. Major Business
    • 2.4.3 Thermo Fisher Scientific Inc. Human High-density Lipoprotein Particles Product and Solutions
    • 2.4.4 Thermo Fisher Scientific Inc. Human High-density Lipoprotein Particles Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Thermo Fisher Scientific Inc. Recent Developments and Future Plans
  • 2.5 Eli Lilly and Company
    • 2.5.1 Eli Lilly and Company Details
    • 2.5.2 Eli Lilly and Company Major Business
    • 2.5.3 Eli Lilly and Company Human High-density Lipoprotein Particles Product and Solutions
    • 2.5.4 Eli Lilly and Company Human High-density Lipoprotein Particles Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Eli Lilly and Company Recent Developments and Future Plans
  • 2.6 Bio-Techne
    • 2.6.1 Bio-Techne Details
    • 2.6.2 Bio-Techne Major Business
    • 2.6.3 Bio-Techne Human High-density Lipoprotein Particles Product and Solutions
    • 2.6.4 Bio-Techne Human High-density Lipoprotein Particles Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Bio-Techne Recent Developments and Future Plans
  • 2.7 Merck
    • 2.7.1 Merck Details
    • 2.7.2 Merck Major Business
    • 2.7.3 Merck Human High-density Lipoprotein Particles Product and Solutions
    • 2.7.4 Merck Human High-density Lipoprotein Particles Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Merck Recent Developments and Future Plans
  • 2.8 Yeasen
    • 2.8.1 Yeasen Details
    • 2.8.2 Yeasen Major Business
    • 2.8.3 Yeasen Human High-density Lipoprotein Particles Product and Solutions
    • 2.8.4 Yeasen Human High-density Lipoprotein Particles Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Yeasen Recent Developments and Future Plans
  • 2.9 Sino Biological
    • 2.9.1 Sino Biological Details
    • 2.9.2 Sino Biological Major Business
    • 2.9.3 Sino Biological Human High-density Lipoprotein Particles Product and Solutions
    • 2.9.4 Sino Biological Human High-density Lipoprotein Particles Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Sino Biological Recent Developments and Future Plans
  • 2.10 Miltenyi Biotec
    • 2.10.1 Miltenyi Biotec Details
    • 2.10.2 Miltenyi Biotec Major Business
    • 2.10.3 Miltenyi Biotec Human High-density Lipoprotein Particles Product and Solutions
    • 2.10.4 Miltenyi Biotec Human High-density Lipoprotein Particles Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Miltenyi Biotec Recent Developments and Future Plans
  • 2.11 Proteintech
    • 2.11.1 Proteintech Details
    • 2.11.2 Proteintech Major Business
    • 2.11.3 Proteintech Human High-density Lipoprotein Particles Product and Solutions
    • 2.11.4 Proteintech Human High-density Lipoprotein Particles Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Proteintech Recent Developments and Future Plans
  • 2.12 BioLegend
    • 2.12.1 BioLegend Details
    • 2.12.2 BioLegend Major Business
    • 2.12.3 BioLegend Human High-density Lipoprotein Particles Product and Solutions
    • 2.12.4 BioLegend Human High-density Lipoprotein Particles Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 BioLegend Recent Developments and Future Plans
  • 2.13 MP Biomedicals
    • 2.13.1 MP Biomedicals Details
    • 2.13.2 MP Biomedicals Major Business
    • 2.13.3 MP Biomedicals Human High-density Lipoprotein Particles Product and Solutions
    • 2.13.4 MP Biomedicals Human High-density Lipoprotein Particles Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 MP Biomedicals Recent Developments and Future Plans
  • 2.14 Molecular Depot
    • 2.14.1 Molecular Depot Details
    • 2.14.2 Molecular Depot Major Business
    • 2.14.3 Molecular Depot Human High-density Lipoprotein Particles Product and Solutions
    • 2.14.4 Molecular Depot Human High-density Lipoprotein Particles Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Molecular Depot Recent Developments and Future Plans
  • 2.15 Biosynth
    • 2.15.1 Biosynth Details
    • 2.15.2 Biosynth Major Business
    • 2.15.3 Biosynth Human High-density Lipoprotein Particles Product and Solutions
    • 2.15.4 Biosynth Human High-density Lipoprotein Particles Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 Biosynth Recent Developments and Future Plans
  • 2.16 Assaypro
    • 2.16.1 Assaypro Details
    • 2.16.2 Assaypro Major Business
    • 2.16.3 Assaypro Human High-density Lipoprotein Particles Product and Solutions
    • 2.16.4 Assaypro Human High-density Lipoprotein Particles Revenue, Gross Margin and Market Share (2021-2026)
    • 2.16.5 Assaypro Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Human High-density Lipoprotein Particles Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Human High-density Lipoprotein Particles by Company Revenue
    • 3.2.2 Top 3 Human High-density Lipoprotein Particles Players Market Share in 2025
    • 3.2.3 Top 6 Human High-density Lipoprotein Particles Players Market Share in 2025
  • 3.3 Human High-density Lipoprotein Particles Market: Overall Company Footprint Analysis
    • 3.3.1 Human High-density Lipoprotein Particles Market: Region Footprint
    • 3.3.2 Human High-density Lipoprotein Particles Market: Company Product Type Footprint
    • 3.3.3 Human High-density Lipoprotein Particles Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Human High-density Lipoprotein Particles Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Human High-density Lipoprotein Particles Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Human High-density Lipoprotein Particles Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Human High-density Lipoprotein Particles Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Human High-density Lipoprotein Particles Consumption Value by Type (2021-2032)
  • 6.2 North America Human High-density Lipoprotein Particles Market Size by Application (2021-2032)
  • 6.3 North America Human High-density Lipoprotein Particles Market Size by Country
    • 6.3.1 North America Human High-density Lipoprotein Particles Consumption Value by Country (2021-2032)
    • 6.3.2 United States Human High-density Lipoprotein Particles Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Human High-density Lipoprotein Particles Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Human High-density Lipoprotein Particles Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Human High-density Lipoprotein Particles Consumption Value by Type (2021-2032)
  • 7.2 Europe Human High-density Lipoprotein Particles Consumption Value by Application (2021-2032)
  • 7.3 Europe Human High-density Lipoprotein Particles Market Size by Country
    • 7.3.1 Europe Human High-density Lipoprotein Particles Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Human High-density Lipoprotein Particles Market Size and Forecast (2021-2032)
    • 7.3.3 France Human High-density Lipoprotein Particles Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Human High-density Lipoprotein Particles Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Human High-density Lipoprotein Particles Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Human High-density Lipoprotein Particles Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Human High-density Lipoprotein Particles Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Human High-density Lipoprotein Particles Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Human High-density Lipoprotein Particles Market Size by Region
    • 8.3.1 Asia-Pacific Human High-density Lipoprotein Particles Consumption Value by Region (2021-2032)
    • 8.3.2 China Human High-density Lipoprotein Particles Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Human High-density Lipoprotein Particles Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Human High-density Lipoprotein Particles Market Size and Forecast (2021-2032)
    • 8.3.5 India Human High-density Lipoprotein Particles Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Human High-density Lipoprotein Particles Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Human High-density Lipoprotein Particles Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Human High-density Lipoprotein Particles Consumption Value by Type (2021-2032)
  • 9.2 South America Human High-density Lipoprotein Particles Consumption Value by Application (2021-2032)
  • 9.3 South America Human High-density Lipoprotein Particles Market Size by Country
    • 9.3.1 South America Human High-density Lipoprotein Particles Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Human High-density Lipoprotein Particles Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Human High-density Lipoprotein Particles Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Human High-density Lipoprotein Particles Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Human High-density Lipoprotein Particles Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Human High-density Lipoprotein Particles Market Size by Country
    • 10.3.1 Middle East & Africa Human High-density Lipoprotein Particles Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Human High-density Lipoprotein Particles Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Human High-density Lipoprotein Particles Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Human High-density Lipoprotein Particles Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Human High-density Lipoprotein Particles Market Drivers
  • 11.2 Human High-density Lipoprotein Particles Market Restraints
  • 11.3 Human High-density Lipoprotein Particles Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Human High-density Lipoprotein Particles Industry Chain
  • 12.2 Human High-density Lipoprotein Particles Upstream Analysis
  • 12.3 Human High-density Lipoprotein Particles Midstream Analysis
  • 12.4 Human High-density Lipoprotein Particles Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Human High-density Lipoprotein Particles. Industry analysis & Market Report on Human High-density Lipoprotein Particles is a syndicated market report, published as Global Human High-density Lipoprotein Particles Market 2026 by Company, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Human High-density Lipoprotein Particles market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,690.04
    		4,035.06
    		5,380.08
    		3,239.88
    		4,859.82
    		6,479.76
    		531,361.20
    		797,041.80
    		1,062,722.40
    		293,712.00
    		440,568.00
    		587,424.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo